http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A case of persistent pulmonary hypertension of the newborn: Treatment with inhaled iloprost
장윤영,박혜진 대한소아청소년과학회 2009 Clinical and Experimental Pediatrics (CEP) Vol.52 No.10
We report a case of a full-term neonate with persistent pulmonary hypertension who developed asphyxia after birth and was treated with iloprost. The neonate had persistent hypoxia and did not respond to supportive treatment. Because inhaled nitric oxide (iNO) was not available in our hospital, inhaled iloprost was administered via an endotracheal tube. This resulted in an immediate elevation of oxygen saturation. Echocardiography revealed the conversion of the right- to-left ductal shunt to the left-to-right one and a decrease of the right ventricular pressure. The use of inhaled iloprost did not cause any significant side effects. Here, we describe our experience where iloprost was used in a neonate with persistent pulmonary hypertension because the standard therapy with inhaled nitric oxide was not available.
( So-young Yoon ),( Eun-soo Yoo ),( Eun-jung Yoo ),( Ju-yang Jung ),( Hyoun-ah Kim ),( Chang-hee Suh ) 대한류마티스학회 2017 대한류마티스학회지 Vol.24 No.2
Pulmonary arterial hypertension is a critical manifestation of systemic sclerosis (SSc) and is a main cause of death. Several treatment modalities for SSc have been identified, with effects that improve quality of life and mortality rates. However, whether these drugs can also normalize pulmonary arterial pressure, remains unclear. Here, we report the case of a woman with diffuse SSc with pulmonary arterial hypertension, who had a functional status equivalent to the New York Heart Association class III. The patient was treated with inhaled iloprost. After six years of inhaled iloprost therapy, echocardiography showed that pulmonary arterial pressure normalized, accompanied by improvement in functional capacity. Inhaled iloprost might not only normalize pulmonary arterial pressure, but also improve the functional status of patients with SSc with pulmonary arterial hypertension. (J Rheum Dis 2017;24:114-118)
우리나라 폐동맥고혈압환자에 대한 Bosentan과 Iloprost의 비용-효용 분석
손현순(Hyun Soon Sohn),이태진(Tae-Jin Lee) 대한약학회 2010 약학회지 Vol.54 No.2
This study was conducted to analyze cost-utility of bosentan versus iloprost indicated for pulmonary arterial hypertension (PAH) in a Korean healthcare setting from a payer’s perspective. We constructed a Markov model to estimate total costs and outcomes for 1-year time horizon in a hypothetical cohort of 50-year-old patients with PAH. Base analysis showed that bosentan resulted in KW 5.5 billions saving and 18 quality-adjusted life year (QALY) gains per 100 patients compared to iloprost. Bosentan as a dominant strategy was found to be robust through various sensitivity analyses.
Inhaled Iloprost as a First-Line Therapy for Persistent Pulmonary Hypertension of the Newborn
김승현,이현주,Nam Su Kim,박현경 대한신생아학회 2019 Neonatal medicine Vol.26 No.4
Purpose: Persistent pulmonary hypertension of the newborn (PPHN) is a potentially fatal disease. Inhaled iloprost, a stable analogue of prostacyclin, has recently been used as a therapeutic option. However, there are no clinical guidelines on the use of iloprost, specifically for neonates. This study aimed to suggest the use of inhaled iloprost as a rescue therapy for PPHN based on our experience. Methods: The efficacy and adverse events of inhaled iloprost were evaluated prospectively in nine full-term neonates with PPHN. We monitored the following parameters: fraction of inspired oxygen (FiO2), respiratory severity score (RSS), heart rate, and mean blood pressure. Results: The inhalation dose was 1 to 2 μg/kg initially, and 4 to 8 inhalations per day were applied over 2 to 8 days, except in the case of one neonate who died 2 days after birth. Echocardiographic findings, changes in FiO2, and RSS improved within the next 7 days in eight of the nine patients. Severe side effects on heart rate and blood pressure were not observed. Conclusion: Our experience suggests that inhaled iloprost can be used as a first-line treatment in newborn infants with PPHN when inhaled nitric oxide is not available. To the best of our knowledge, this report is the first prospective case series on the use of inhaled iloprost in PPHN.
황승경,오영철,김남수,박현경,염명걸 대한심장학회 2009 Korean Circulation Journal Vol.39 No.8
Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmonary dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for 4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. Inhaled iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable. Pulmonary artery hypertension is a common cardiovascular complication in preterm infants with bronchopulmonary dysplasia which is associated with increased morbidity and mortality. Inhaled iloprost is used as a therapeutic option in pulmonary hypertension, especially in adults. There have been but a few reports on the use of iloprost for neonates and infants. We report the case of a 5 month-old-male infant who received neonatal intensive care for 4 months due to respiratory distress syndrome and prematurity, during which he developed bronchopulmonary dysplasia. Echocardiography showed severe pulmonary hypertension. The initial treatment included respiratory support with high frequency oscillatory ventilation (HFOV); however, his clinical condition did not improve. Inhaled iloprost with sildenafil, an oral phosphodiesterase-5 inhibitor, was thus used. With the administration of iloprost and sildenafil, his condition improved and he was weaned from oxygen. Our clinical experience suggests that iloprost is a promising therapy for pulmonary hypertension, especially when inhaled nitric oxide is unavailable.
일산화질소 흡입요법에 반응하지 않는 중증 신생아 지속성 폐동맥 고혈압증 환자에서 분무식 iloprost (Ventavis(R))의 치료효과
한윤기 ( Yoon Ki Han ),이순민 ( Soon Min Lee ),은호선 ( Ho Seon Eun ),김정은 ( Jeong Eun Kim ),남궁란 ( Ran Namgung ),박민수 ( Min Soo Park ),박국인 ( Kook In Park ),이철 ( Chul Lee ) 대한주산의학회 2011 Perinatology Vol.22 No.1
Inhaled iloprost, a stable carbacyline derivative of prostacyclin, has been used recently for the treatment of adults with pulmonary hypertension but only few reports are available about its use in neonatal critical care. We report therapeutic trial of inhaled iloprost in newborn infants with persistent pulmonary hypertension of the newborn (PPHN) who did not respond to inhaled nitric oxide (iNO). Inhaled iloprost (Ventavis(R), Bayer Shering Pharma, Germany) was effective in neonates with severe PPHN who showed inadequate response to iNO. We suggest that inhaled iloprost could be considered as an additional therapeutic option in PPHN refractory to iNO.
Inhaled iloprost for the treatment of patient with Fontan circulation
Kim, Yong Hyun,Chae, Moon Hee,Choi, Deok Young The Korean Pediatric Society 2014 Clinical and Experimental Pediatrics (CEP) Vol.57 No.10
Decreased exercise capacity after Fontan surgery is relatively common and the failure of the Fontan state gradually increases with age. However, there is no further treatment for patients with Fontan circulation. Pulmonary vasodilation therapy is an effective method to solve this problem because pulmonary vascular resistance is a major factor of the Fontan problem. Inhaled iloprost is a chemically stable prostacyclin analogue and a potent pulmonary vasodilator. We experienced two cases of Fontan patients treated with inhaled iloprost for 12 weeks. The first patient was an 18-year-old female with pulmonary atresia with an intact ventricular septum, and the second patient was a 22-year-old male with a double outlet right ventricle. Fifteen years have passed since both patients received Fontan surgery. While the pulmonary pressure was not decreased significantly, improved exercise capacity and cardiac output were observed without any major side effects in both patients. The iloprost inhalation therapy was well tolerated and effective for the symptomatic treatment of Fontan patients.
Inhaled iloprost for the treatment of patient with Fontan circulation
김용현,채문희,최덕영 대한소아청소년과학회 2014 Clinical and Experimental Pediatrics (CEP) Vol.57 No.10
Decreased exercise capacity after Fontan surgery is relatively common and the failure of the Fontanstate gradually increases with age. However, there is no further treatment for patients with Fontancirculation. Pulmonary vasodilation therapy is an effective method to solve this problem becausepulmonary vascular resistance is a major factor of the Fontan problem. Inhaled iloprost is a chemicallystable prostacyclin analogue and a potent pulmonary vasodilator. We experienced two cases of Fontanpatients treated with inhaled iloprost for 12 weeks. The first patient was an 18-year-old female withpulmonary atresia with an intact ventricular septum, and the second patient was a 22-year-old malewith a double outlet right ventricle. Fifteen years have passed since both patients received Fontansurgery. While the pulmonary pressure was not decreased significantly, improved exercise capacity andcardiac output were observed without any major side effects in both patients. The iloprost inhalationtherapy was well tolerated and effective for the symptomatic treatment of Fontan patients.
김수남,최덕영 대한소아청소년과학회 2010 Clinical and Experimental Pediatrics (CEP) Vol.53 No.1
A 47-year-old male patient in whom atrial septal defect (ASD) had been diagnosed 15 years previously was admitted for cardiac catheterization. He had definite cyanotic lips and nail beds and severe pulmonary arterial hypertension (PAH). He had received medical treatment only for the last few years after being diagnosed with Eisenmenger syndrome. After cardiac catheterization, he received iloprost inhalation therapy pre and postoperation and was discharged after successful surgical closure of the ASD.